<DOC>
	<DOCNO>NCT00099125</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy , temozolomide irinotecan , work different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well radiation therapy , temozolomide , irinotecan work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy , Temozolomide , Irinotecan Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient newly diagnose supratentorial glioblastoma multiforme treat radiotherapy temozolomide follow temozolomide irinotecan historical control RTOG database . - Determine short- long-term toxicity regimen patient . - Determine progression-free survival patient treat regimen . OUTLINE : This multicenter study . - Chemoradiotherapy : Patients undergo radiotherapy daily , 5 day week , 6 week . Concurrently radiotherapy , patient receive oral temozolomide daily , 7 day week , 6 week . - Post-radiotherapy chemotherapy : Beginning 4-6 week completion chemoradiotherapy , patient receive irinotecan IV day 1 15 oral temozolomide daily day 1-5 . Treatment repeat every 28 day 1 year absence disease progression unacceptable toxicity . Patients follow every 2 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 157 patient accrue study within 11 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose supratentorial glioblastoma multiforme surgical biopsy excision No glioma grade less glioblastoma multiforme No recurrent malignant glioma No tumor foci tentorium beyond cranial vault Study therapy must begin ≤ 5 week surgery PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy At least 8 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL* Hematocrit ≥ 30 % * NOTE : *Transfusion allow Hepatic Bilirubin ≤ 0.5 mg/dL ALT AST ≤ 2 time upper limit normal Renal Creatinine ≤ 1.5 mg/dL BUN ≤ 25 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception 2 month study participation No AIDS No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix bladder No major medical illness psychiatric impairment would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent sargramostim ( GMCSF ) Chemotherapy No concurrent chemotherapy Endocrine therapy Concurrent steroid therapy allow provided patient stable decrease dose least 2 week study entry Radiotherapy No prior radiotherapy head neck result overlap radiotherapy field Prior radiotherapy stage T1 glottic cancer allow Surgery See Disease Characteristics Recovered prior surgery Other No enzymeinducing antiepileptic drug within 14 day initiation irinotecan Concurrent nonenzymeinducing antiepileptic drug allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>